CD16 (FCGR3A) Mouse Monoclonal Antibody [Clone ID: GRM1]

CAT#: AM08159PU-N

CD16 (FCGR3A) mouse monoclonal antibody, clone GRM1, Purified

Conjugation: Unconjugated Biotin FITC PE



Need it in bulk or conjugated?
Get a free quote

CNY 2,240.00


货期*
4周

规格
    • 100 ug

Product images

Specifications

Product Data
Clone Name GRM1
Applications FC, IHC, IP, WB
Recommend Dilution Flow Cytometry: < / = 1 µg/10e6 cells.
Immunohistochemistry on Frozen Sections.
Western Blotting (Non-reducing conditions).
Immunoprecipitation.
Reactivity Human
Host Mouse
Clonality Monoclonal
Specificity This antibody recognizes CD16/FcgammaRIII.
Formulation 100 mM Borate Buffered Saline, pH 8.2.
No preservatives or amine-containing buffer salts added.
State: Purified
State: Liquid purified Ig fraction.
Concentration lot specific
Conjugation Unconjugated
Storage Condition Store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer.
Avoid repeated freezing and thawing.
Gene Name Fc fragment of IgG receptor IIIa
Background CD16 (FcgammaRIII) serves as a low affinity IgG receptor. Human CD16 is expressed in two forms CD16a and CD16b. CD16a is a transmembrane protein of monocytes, macrophages, NK cells and a subset of T cells. CD16b is a GPI-linked monomeric receptor expressed on neutrophils and is involved in their activation and induction of a proadhesive phenotype.
CD16 is involved in NK activation and signal transduction. (Ref.1-5)
Synonyms FCGR3A, CD16A, FCG3, FCGR3, IGFR3, Fc-gamma RIII-alpha, Fc-gamma RIII, Fc-gamma RIIIa, FcRIII, FcRIIIa, FcR-10, IgG Fc receptor III-2
Reference Data
Protein Families ES Cell Differentiation/IPS, Secreted Protein, Transmembrane
Protein Pathways Fc gamma R-mediated phagocytosis, Natural killer cell mediated cytotoxicity, Systemic lupus erythematosus
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.
Customer Reviews 
Loading...